Novo Nordisk NVO Stock Analysis
- NYSE
- Stock
- Market open · no trades yet today
$40.30 down $1.88, 4.46% at close Nov 5
Last close · Previous close $42.18
- Market cap
- At the Nov 5 close
- P/E ratio
- 9.94On last 12 months’ EPS
- Diluted EPS
- $4.06Last 12 months
- Dividend yield
- 4.46%Last 12 months
Price chart
$40.30down $1.88, 4.46%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$42.18Nov 4
- Volume18.50MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume11.22MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $35.12 to $64.16; now $40.30
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
NVO beat the S&P 500 in 1 of 7 periods.
| Period | NVO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NVO: up 7.4% S&P 500: down 5.4% | NVO beat the S&P 500 by 12.8 percentage points Beat |
| 3M | NVO: down 8.3% S&P 500: down 4.5% | NVO trailed the S&P 500 by 3.8 percentage points Trailed |
| YTD | NVO: down 17.0% S&P 500: up 8.3% | NVO trailed the S&P 500 by 25.3 percentage points Trailed |
| 1Y | NVO: down 12.9% S&P 500: up 9.3% | NVO trailed the S&P 500 by 22.2 percentage points Trailed |
| Long term | ||
| 3Y | NVO: down 55.3% S&P 500: up 74.8% −23.6% vs +20.5% a year | NVO trailed the S&P 500 by 130.1 percentage points Trailed |
| 5Y | NVO: down 20.5% S&P 500: up 67.3% −4.5% vs +10.8% a year | NVO trailed the S&P 500 by 87.8 percentage points Trailed |
| 10Y | NVO: up 190.2% S&P 500: up 311.8% +11.2% vs +15.2% a year | NVO trailed the S&P 500 by 121.6 percentage points Trailed |
$10,000 invested in NVO 10 years ago (Nov 4, 2016) would be worth about $29,017 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,184.
NVO beat the S&P 500 in 1 of 7 periods.
| Period | NVO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NVO: up 7.4% S&P 500: down 5.4% | NVO beat the S&P 500 by 12.8 percentage points Beat |
| 3M | NVO: down 9.5% S&P 500: down 4.8% | NVO trailed the S&P 500 by 4.7 percentage points Trailed |
| YTD | NVO: down 20.8% S&P 500: up 7.5% | NVO trailed the S&P 500 by 28.3 percentage points Trailed |
| 1Y | NVO: down 16.8% S&P 500: up 8.2% | NVO trailed the S&P 500 by 25.0 percentage points Trailed |
| Long term | ||
| 3Y | NVO: down 58.9% S&P 500: up 68.6% −25.7% vs +19.0% a year | NVO trailed the S&P 500 by 127.5 percentage points Trailed |
| 5Y | NVO: down 28.9% S&P 500: up 56.4% −6.6% vs +9.4% a year | NVO trailed the S&P 500 by 85.3 percentage points Trailed |
| 10Y | NVO: up 134.6% S&P 500: up 251.5% +8.9% vs +13.4% a year | NVO trailed the S&P 500 by 116.9 percentage points Trailed |
$10,000 invested in NVO 10 years ago (Nov 4, 2016) would be worth about $23,464 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,147.
All-time high
$146.91
Closing high on . Now 72.6% below that record.
Split-adjusted daily closes since Jan 4, 1982.
Stock splits
5
Latest: 2-for-1 on . One share bought before the first split is 200 shares today.
All 5 splits
- 2-for-1
- 5-for-1
- 2-for-1
- 5-for-2
- 4-for-1
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $51.07Bup 11.3%
- Net income
- $18.03Bup 10.3%
- Diluted EPS
- $4.06up 10.5%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $10.52B | $4.03B | $0.90 |
| Q4 FY24 (Dec 31, 2024) | $11.95B | $3.94B | $0.88 |
| Q1 FY25 (Mar 31, 2025) | $11.33B | $4.21B | $0.95 |
| Q2 FY25 (Jun 30, 2025) | $12.08B | $4.17B | $0.94 |
| Q3 FY25 (Sep 30, 2025) | $11.79B | $3.15B | $0.71 |
| Q4 FY25 (Dec 31, 2025) | $12.44B | $4.23B | $0.95 |
| Q1 FY26 (Mar 31, 2026) | $14.85B | $7.45B | $1.67 |
| Q2 FY26 (Jun 30, 2026) | $11.98B | $3.20B | $0.73 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $21.33B | $7.24B | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $25.50B | $8.00B | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $34.41B | $12.40B | $2.76 |
| FY24 (Dec 31, 2024) | $40.50B | $14.08B | $3.16 |
| FY25 (Dec 31, 2025) | $48.59B | $16.11B | $3.62 |
Margins
- Gross 80.6%
- Operating 43.1%
- Net 35.3%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $11.86BLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$20.57BLast 12 months
- Capital spending$8.71BLast 12 months
- 23.2%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $902.30MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$8.04BLast 12 months
- Total returned$8.94BLast 12 months
75% of free cash flow
Balance sheet
- $7.22BAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$21.39BAs of Jun 30, 2026
- Net debt$14.17BAs of Jun 30, 2026
- 0.87As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.63As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✓Share count didn’t rise: passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 59.0%Last 12 months
Over the last 12 months, Novo Nordisk’s net income was 59.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return. ROE can run this high when equity is small, for example after years of large share buybacks.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 21.1%Last 12 months
Over the last 12 months, Novo Nordisk’s net income was 21.1% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.52 |
| 2017 | $0.41 |
| 2018 | $0.34 |
| 2019 | $0.62 |
| 2020 | $0.65 |
| 2021 | $0.75 |
| 2022 | $0.81 |
| 2023 | $1.04 |
| 2024 | $1.45 |
| 2025 | $1.68 |
| 2026 (to date) | $1.80 |
Dividend details
- $1.80Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- Dividend yield4.46%Last 12 months
- $0.58Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- FrequencySemiannual2 payments in the last 12 months
- up 20.9% a yearFull years 2020–2025
The compound annual growth rate of the full-year dividend per share from 2020 to 2025.
- 6 yearsThrough 2025
How many calendar years in a row the full-year amount has risen, through 2025.
- 44.3%Last 12 months
The share of earnings paid out as dividends over the last 12 months. Lower ratios leave more room to reinvest or raise the dividend.
Payout = Dividends per share ÷ Diluted EPS (both last 12 months)Payout ratio calculator
About Novo Nordisk
Novo Nordisk is a leading global health care company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Denmark
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
NVO news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
NVO stock FAQ
What is NVO stock’s price today?
Novo Nordisk (NVO) traded at $40.30 at the close on , down $1.88 (4.46%) from the previous close of $42.18. Over the past 52 weeks it has traded between $35.12 and $64.16.
If you invested $1,000 in NVO 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in NVO on would be worth about $2,902 at the close on , a total return of +190.2%. The same $1,000 would be worth $795 if invested five years ago, $871 if invested one year ago, $14,793 if invested 20 years ago, and $73,892 if invested 30 years ago. Past performance doesn’t predict future returns.
What is NVO’s P/E ratio?
NVO trades at 9.9 times its diluted earnings over the four quarters to ($4.06 per share), at the close. (How the P/E ratio works.)
How much revenue does Novo Nordisk make?
Novo Nordisk reported $51.1 billion of revenue over the four quarters to , up 11.3% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $12.0 billion, down 0.8% from a year earlier.
Is Novo Nordisk profitable?
Yes. Novo Nordisk earned $18.0 billion of net income over the four quarters to , a net margin of 35.3%, and its operating margin was 43.1% (what margins tell you).
What are NVO’s earnings per share?
NVO’s diluted earnings per share were $4.06 over the four quarters to , compared with $3.67 in the twelve months before. The latest quarter (Q2 FY26) brought $0.73 per share, against $0.94 a year earlier (how EPS works).
Does NVO pay a dividend?
Yes. Novo Nordisk pays a semiannual dividend. The most recent was $0.58 per share, with an ex-dividend date of . Over the last twelve months it paid $1.80 per share, a 4.46% yield at the close, and the full-year dividend has risen 6 years in a row (how dividend yield works).
Based on the last 12 months’ payments ($1.80 per share), and if the next 12 months match the last 12, 100 shares would receive about $180 over 12 months, and $1,000 over 12 months would take about 557 shares, roughly $22,447 at the close. Dividends can change.
What is NVO’s 52-week high and low?
Over the past 52 weeks NVO has traded as low as $35.12 and as high as $64.16. At $40.30 at the close on , it is 37.2% below that high and 14.7% above the low.
What is NVO’s all-time high?
NVO’s highest closing price was $146.91 on , adjusted for stock splits. At $40.30 at the close on , it is 72.6% below that record.
Has NVO stock ever split?
Yes, five times: 4-for-1 on ; 5-for-2 on ; 2-for-1 on ; 5-for-1 on ; 2-for-1 on . One share bought before the first split would be 200 shares today.
How has NVO stock performed?
Including dividends and measured to the close on , NVO has returned −17.0% so far this year and −12.9% over the past year, and −20.5% over five years (−4.5% a year). Over the same periods the S&P 500, measured by SPY, returned +8.3%, +9.3% and +67.3%. Past performance doesn’t predict future returns.
What sector and industry is Novo Nordisk in?
Novo Nordisk is in the Healthcare sector and the Biotechnology industry, and is headquartered in Denmark.
What exchange does NVO trade on?
Novo Nordisk trades on the NYSE under the ticker symbol NVO. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.